- New treatment options for chronic kidney disease - focused on SGLT2 inhibitors2021 | First Faculty of Medicine
- Sodium glucose co-transporter-2 inhibitors in heart failure: beyond glycaemic control. The Position Paper of the Heart Failure Association of the European Society of Cardiology - summary of the document prepared by CKS2020 | First Faculty of Medicine
- Glifloziny - jaké zaujímají postavení v roce 2020?2020 | Third Faculty of Medicine
- Glifloziny v léčbě srdečního selhání: aktuality a perspektivy2022 | First Faculty of Medicine
- Empagliflozin u pacientů s chronickým onemocněním ledvin - studie EMPA-KIDNEY2023 | Third Faculty of Medicine
- Farmakoterapie arteriální hypertenze u pacientů s diabetes mellitus 2. typu2022 | First Faculty of Medicine
- Farmakoterapie arteriální hypertenze u obézních pacientů s diabetes mellitus 2. typu2023 | First Faculty of Medicine
- News in the treatment of heart failure - gliflozins in patients with a mildly reduced and preserved ejection fraction2023 | First Faculty of Medicine
- Komentář ke studii (Empagliflozin a progrese onemocnění ledvin u pacientů s diabetes mellitus 2. typu - studie EMPA-REG OUTCOME)2016 | First Faculty of Medicine
- Novější antidiabetika z pohledu nefrologa: zaměřeno na dapagliflozin2022 | First Faculty of Medicine
- CAPTURE: CVD prevalence in adults with type 2 diabetes in the Czech Republic2022 | First Faculty of Medicine